Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?
about
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft modelProtective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivoThe ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasisZoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers.Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophagesAnti-tumour activity of bisphosphonates in preclinical models of breast cancer.Metastasis and bone loss: advancing treatment and prevention.Role of IL-1 receptor-associated kinase-M (IRAK-M) in priming of immune and inflammatory responses by nitrogen bisphosphonates.A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitroDrugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts.Small molecules for bone diseases.Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.Nanomedicine Strategies to Target Tumor-Associated Macrophages.Direct implantation of VX-2 carcinoma: a new rabbit bone model using a three-dimensional matrix as a carrier for the tumor cells.
P2860
Q27302940-1F5CD67A-3E74-4748-909C-8F230E232C2DQ30881569-97E6BF95-61E1-4B3F-BFBD-447C8CD8E5BCQ33692900-B404BF15-7D93-43D2-B870-1C2DBEAFE7D7Q33786905-8C9AC21E-59C6-4C3E-8116-0FC4555A5D77Q34024176-D211C661-3D1A-4DB4-9E67-FFEF22AE7DBFQ34025648-12D6F35B-F55A-4445-8F79-2CA802B6FCA8Q34044797-15736929-DE44-4B64-91C6-8433319A723EQ34613492-F5AF4504-1DE4-4CEB-8668-060169B5FDA3Q34617837-C9992CEC-D04C-4A55-A802-CE33FFBB184CQ35091107-1C9B78C1-BDFA-4C3F-A195-6AB7FE72E0EEQ36110948-CBD8ABAE-8593-4E53-A5FC-DBA0E658BA34Q36278275-E75993BD-AE3F-470B-AE76-1DF11865FB9EQ36491378-A594E5E9-FB81-40A9-96B3-11766F4C3B54Q37714909-4A774AEA-A19F-4DCD-836E-B6683E60C683Q37974937-85115BB4-3081-4128-951C-CAB647BDA1BCQ38818271-3281E27E-C3AA-4C0A-809A-A220B02CA69CQ39283111-6477D4B1-AFD6-40FA-B7FA-8302899C41EFQ39467274-15B2CA51-C275-4DC1-B4D9-B62EF783D274
P2860
Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?
@en
Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?
@nl
type
label
Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?
@en
Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?
@nl
prefLabel
Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?
@en
Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?
@nl
P1476
Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?
@en
P2093
P304
P356
10.2174/156800909789760339
P577
2009-11-01T00:00:00Z